eXoZymes posts investor deck for proposed offering

eXoZymes Inc. filed a current report to share an updated investor presentation dated May 7, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

eXoZymes Inc. filed a current report to share an updated investor presentation dated May 7, 2026. The presentation is being provided to potential underwriters, other offering participants, and investors in connection with a proposed public offering of the company’s securities.

The report lists the presentation as Exhibit 99.1 and includes a cover page interactive data file as Exhibit 104. eXoZymes is a Nevada corporation whose common stock trades on the Nasdaq Capital Market under the symbol EXOZ.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Investor Presentation, proposed public offering, Emerging growth company, Nasdaq Capital Market, +1 more

5 terms

Investor Presentation financial

"Attached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, as of May 7, 2026"

An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.

proposed public offering financial

"being provided to the potential underwriters and other offering participants and investors for a proposed public offering of securities"

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nasdaq Capital Market financial

"Common Stock | | EXOZ | | Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Cover Page Interactive Data File regulatory

"104 | | Cover Page Interactive Data File (embedded within the Inline XBRL Document)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did eXoZymes Inc. (EXOZ) disclose in this 8-K filing?

eXoZymes Inc. furnished an updated investor presentation as an exhibit. The presentation is dated May 7, 2026 and is being used with potential underwriters, offering participants, and investors in connection with a proposed public offering of the company’s securities.

What is the purpose of eXoZymes Inc.’s May 7, 2026 investor presentation?

The investor presentation is intended for potential underwriters, other offering participants, and investors. It supports discussions around a proposed public offering of eXoZymes Inc. securities and is formally included in the 8-K filing as Exhibit 99.1.

Which exhibits are included in eXoZymes Inc. (EXOZ) May 7, 2026 8-K?

The filing includes Exhibit 99.1, an investor presentation of eXoZymes Inc. as of May 7, 2026. It also includes Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document for the current report.

How is eXoZymes Inc. (EXOZ) preparing for a proposed public offering?

eXoZymes Inc. is providing an investor presentation to potential underwriters and other offering participants. This presentation, dated May 7, 2026, outlines information about the company and its proposed public offering of securities and is attached to the 8-K as Exhibit 99.1.

On which exchange is eXoZymes Inc. (EXOZ) common stock listed?

eXoZymes Inc.’s common stock is listed on the Nasdaq Capital Market. The 8-K filing specifies that the company’s common shares trade under the symbol EXOZ, confirming its public listing on this U.S. equity market segment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/07/2026 - 06:08 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 7, 2026

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

Nevada

001-42204

83-4550057

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (626) 415-1488

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		EXOZ		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 — Other Events.

Attached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, as of May 7, 2026, that is being provided to the potential underwriters and other offering participants and investors for a proposed public offering of securities by the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits		Description of Exhibit

99.1		Investor Presentation of eXoZymes Inc. as of May 7, 2026.

104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.